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attractive approach to eliminating residual disease after allogeneic
hematopoietic stem-cell transplant, adoptive immunotherapy after
UCBT is constrained by the anonymity of the donor and difﬁculty
of generating antigen-speciﬁc T cells from functionally naïve um-
bilical cord blood (UCB)-derived T cells. Therefore, to generate
T cells that recognize B-ALL, we have developed chimeric antigen
receptors (CARs) to redirect the speciﬁcity of T cells for CD19, a
B-lineage antigen, and expressed these transgenes in UCB-derived
T cells. An ex vivo process, which is compliant with current good
manufacturing practice for T-cell trials, has been developed to
genetically modify and numerically expand UCB-derived T cells
into CD19-speciﬁc effector cells. These are capable of CD19-
restricted cytokine production and cytolysis in vitro, as well as
mediating regression of CD19 tumor and being selectively elim-
inated in vivo. These data provide the rationale for infusing UCB-
derived CAR CD19-speciﬁc T cells after UCBT to reduce the
incidence of CD19 B-ALL relapse.
Part of this research was originally published in Blood. Serrano LM,
Pfeiffer T, Olivares S, et al. Differentiation of naive cord-blood T
cells into CD19-speciﬁc cytolytic effectors for post-transplantation
adoptive immunotherapy. Reprinted in part from Blood 2006;107(7):
2643-52. © American Society of Hematology. Part of this research is
under consideration for publication by Cancer Research.
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Though cord blood (CB) is an accepted alternative to bone
marrow (BM) for hematopoietic stem cell transplantation (HSCT)
in children, the selection of CB over BM remains controversial.
Therefore, we compared the results of 492 unrelated donor BM
and 508 CB transplants in patients younger than 16 years of age
and transplanted in the US between 1995 and 2003. Seventy ﬁve
percent of BM transplants were matched (HLA A, B, low/inter-
mediate resolution, DRB1) and 93% of CB transplants were mis-
matched at 1 or 2 HLA loci.
Hematopoietic recovery was lower after mismatched and low cell
dose CB than after BM transplants. Acute GVHD rates were
higher after BM and mismatched CB transplants than matched CB
transplants. Chronic GVHD was signiﬁcantly lower after matched
or mismatched CB transplants. Recipients of matched CB trans-
plants had signiﬁcantly lower transplant related mortality (TRM),
treatment failure and overall mortality than recipients of matched
BM; recipients of high cell dose CB mismatched at 1 locus had
risks similar to recipients of matched BM. Recipients of low cell
dose CB mismatched at 1 locus and CB mismatched at 2 loci (any
cell dose) had higher risks of TRM, treatment failure and mortality
than matched BM recipients during the early post transplant pe-
riod. However, among those surviving the early period, subsequent
risks were similar to matched BM recipients. A similar trend was
observed in a sub-set analysis where outcomes after CB transplants
were compared with BM transplants matched at 8 HLA-loci.
These data support use of CB matched or mismatched at 1 locus
with a high cell dose for children needing HSCT, whether or not
a matched BM donor is available; low cell dose or 2-loci mis-
matched CB grafts may provide a reasonable alternative when a
matched BM donor is not available or for those whose disease
requires immediate transplantation.
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Unrelated cord blood transplantation (UCBT) is an alternative
option to treat children with haematological diseases without an
HLA-identical donor. Few data is available on the outcomes after
UCBT in children with ALL. We have analyzed total of 323
children with ALL receiving an UCBT, from 1994 to 2004 in 99
transplant centres in 24 countries, mostly in Europe (Table 7).
Cumulative incidence with competing risk and KM estimates
Table 7. Patient and Treatment Characteristics and Outcomes in 323 Children with ALL
Characteristics CR1 (n  76) CR2 (n  136) Advanced Phase (n  111)
Age (y), median (range) 4.7 (0.4-16) 6.7 (0.7-16) 8.0 (0.5-16)
Immunophenotype
Pre-B/B/T/null or biphenoptypic (%) 18%/47%/17%/15% 17%/57%/17%/8% 10%/67%/12%/5%
Previous autologous transplant, n (%) 1 (1%) 5 (4%) 20 (18%)
Karyotype, n (%)
Not available 5 (7%) 35 (26%) 31 (28%)
Normal 14 (18%) 53 (39%) 37 (33%)
Abnormal 57 (75%) 48 (35%) 43 (39%)
Good and intermediate risk 6 (11%) 32 (57%) 25 (58%)
Poor risk 51 (89%) 16 (33%) 18 (42%)
Median time from diagnosis to UCBT (mo) 6 28 33
HLA disparities (6/6), n (%)
0 10 (14%) 14 (11%) 10 (10%)
1 29 (42%) 61 (48%) 47 (47%)
2 27 (39%) 47 (37%) 40 (39%)
>2 3 (4%) 4 (3%) 4 (4%)
Median nucleated cell dose infused (107/kg) 5.3 3.7 3.4
TBI-based regimen 39 (51%) 107 (79%) 68 (61%)
Follow-up (mo), median (range) 17 (3-60) 29 (3-93) 23 (3-96)
Outcomes
Neutrophil recovery at day 60 75  5% 85  3% 65  5%
Acute GVHD (II-IV) at day 100 46  6% 43  4% 36  5%
Chronic GVHD at 2 years 15  4% 16  3% 12  3%
TRM at day 100 22  5% 25  4% 34  5%
Relapse at 2 years 34  8% 37  5% 48  7%
LFS at 2 years 42  6% 41  4% 24  4%
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